AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Amazon Explores AI Content Marketplace With Media Publishers 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SAN FRANCISCO, Nov. 15, 2017 -- Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17.
Included in this article is: DURECT Corp. (NASDAQ:DRRX)
A Nov. 2 research report by Zeng for Zacks Small Cap Research indicated that DURECT Corp. total Q3/17 revenue was $20.7 million versus $3.7 million in Q3/16, and all forms of revenue were up year over year. DURECT's reported net income for Q3/17 was $6.1 million. This compares to a net loss of $8.8 million in Q3/16.
In Q3/17, research and development (R&D) collaborations generated $5.6 million versus $0.4 million in Q3/16. "A large portion of that increase [is] related to the recognition of deferred revenue from upfront fees already received by the company," Zeng wrote.
Continue reading this article: Analyst Says Biotech Share Price Could Potentially 'Double'
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Durect Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: Analyst Says Biotech Share Price Could Potentially 'Double'
Contact Information: Carrie Beal Amaro- Publisher ([email protected])
